A phase I study of toremifene.
A Phase I study of the new antiestrogenic drug toremifene was carried out in 27 Japanese women, using oral doses of 10-480 mg per day for one or five days. Serum concentrations reached a dose-dependent maximum 2-6 hours after each oral administration. Side effects were generally mild.
Tominaga
T
T
Tokyo Metropolitan Komagome Hospital, Japan.
Abe
O
O
Izuo
M
M
Nomura
Y
Y
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007564:Japan; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D017312:Toremifene
D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene